EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Daisuke Asaoka, Shin Yoshimoto, Noriko Katsumata iD, Noriyuki Iwabuchi, Naotake Yanagisawa, Toshitaka Odamaki iD, Jin-Zhong Xiao iD, Tsutomu Takeda iD, Shigeo Koido iD, Toshifumi Ohkusa, Akihito Nagahara iD, Nobuhiro Sato

Nutrients · 2026

DOI: 10.3390/nu18183074 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2026. Verfasst von Daisuke Asaoka und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, Faculty of Medicine, Juntendo University, Tokyo 136-0075, Japan. Hauptthemen laut MEDLINE: Sarcopenia, Bifidobacterium breve, Muscle, Skeletal, Probiotics. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Morinaga (Japan), Morinaga Milk Industry Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Sarcopenia contributes to frailty and functional decline in older adults; however, effective adjunctive strategies remain limited. Heat-killed Bifidobacterium breve B-3 (B-3HK), a postbiotic, has shown muscle-related effects in preclinical studies; however, clinical evidence in patients with established sarcopenia is scarce. This pilot trial aimed to evaluate these clinical effects.

Methods

In this 24-week randomized, double-blind, placebo-controlled trial, adults aged 50–89 years with Asian Working Group for Sarcopenia (AWGS) 2019-defined sarcopenia received B-3HK (2 × 1010 cells/day) or placebo daily. The primary outcome was the change in knee extension strength at week 24. Secondary outcomes included body composition measured using bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), physical performance, Eating Assessment Tool-10 (EAT-10), serum biomarkers, gut microbiota, and safety. Secondary outcomes were exploratory with nominal p-values and no adjustment for multiple comparisons.

Results

Fifty participants were randomized, and 49 were included in the full analysis set. Compared with placebo, B-3HK did not significantly improve knee extension strength. Exploratory analyses showed between-group differences favoring B-3HK in the BIA-derived skeletal muscle mass index, limb muscle mass, EAT-10 score, and serum insulin-like growth factor-1 and 25-hydroxyvitamin D levels. These differences were primarily driven by the attenuation of the decline in the placebo group and were not corroborated by DXA-derived indices or functional outcomes. The gut microbiota composition did not differ between groups. No serious adverse events were observed.

Conclusions

B-3HK did not improve muscle strength in patients with sarcopenia. Exploratory analyses identified nominal between-group differences in body composition and endocrine outcomes; however, these findings were unadjusted for multiplicity and should be regarded as hypothesis-generating rather than confirmatory evidence of efficacy. These data may help inform the design of future adequately powered trials, but confirmation is required before any therapeutic benefit can be inferred.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaBifidobacterium breveMuscle, SkeletalProbioticsHumansDouble-Blind MethodAgedPilot ProjectsMiddle AgedFemaleMaleAged, 80 and overMuscle StrengthBody CompositionHot TemperatureTreatment OutcomeAbsorptiometry, PhotonBiomarkers

Stichwörter der Autor:innen

IGF-1MCC1274bioelectrical impedance analysisgut–muscle axisheat-killed Bifidobacterium breve B-3postbioticrandomized controlled trialsarcopeniaskeletal muscle mass

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Gastroenterology, Juntendo Tokyo Koto Geriatric Medical Center, Faculty of Medicine, Juntendo University, Tokyo 136-0075, Japan.
  • Biotics Research Institute, Morinaga Milk Industry Co., Ltd., Kanagawa 252-8583, Japan.
  • Medical Technology Innovation Center, Juntendo University, Tokyo 113-8421, Japan.
  • Morinaga Milk Industry Co., Ltd., Tokyo 105-7122, Japan.
  • Department of Gastroenterology, Faculty of Medicine, Juntendo University, Tokyo 113-8421, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Chiba 277-0004, Japan.

ORCID-Profile: Noriko Katsumata, Toshitaka Odamaki, Jin-Zhong Xiao, Tsutomu Takeda, Shigeo Koido, Akihito Nagahara

Förderung

  • Morinaga (Japan)
  • Morinaga Milk Industry Co., Ltd.

Zitieren

APA

Asaoka, D., Yoshimoto, S., Katsumata, N., Iwabuchi, N., Yanagisawa, N., Odamaki, T., Xiao, J. Z., Takeda, T., Koido, S., Ohkusa, T., Nagahara, A., & Sato, N. (2026). Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. Nutrients. https://doi.org/10.3390/nu18183074

Vancouver

Asaoka D, Yoshimoto S, Katsumata N, Iwabuchi N, Yanagisawa N, Odamaki T, et al. Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial. Nutrients. 2026. doi:10.3390/nu18183074

BibTeX
@article{Asaoka2026,
  author = {Asaoka, Daisuke and Yoshimoto, Shin and Katsumata, Noriko and Iwabuchi, Noriyuki and Yanagisawa, Naotake and Odamaki, Toshitaka and Xiao, Jin-Zhong and Takeda, Tsutomu and Koido, Shigeo and Ohkusa, Toshifumi and Nagahara, Akihito and Sato, Nobuhiro},
  title = {Effects of Heat-Killed Bifidobacterium breve B-3, a Postbiotic, on Muscle Mass-Related Parameters in Patients with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18183074}
}
Kostenlos starten →